A randomized double-blind placebo controlled 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-2)

This is a 52 wk, randomized, double-blind study to demonstarte the clinical efficacy, safety, and tolerability of ianalumab compared to placebo in patients with active Sjogren's syndrome. Pts will receive a subcutaneous injection of ianalumab/placebo monthly, in addition to salivary flow assessments, blood and urine sampling, PROs, and optional assessments for cognitive function.

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Medical Research
• Age: - 99 Years
• Gender: All